期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

色素上皮衍生因子对骨肉瘤治疗的作用 被引量：3

The role of PEDF in the treatment for osteosarcoma
暂未订购
导出
摘要 骨肉瘤是一种好发于青少年的常见骨骼系统恶性肿瘤。骨肉瘤的生长和转移主要依赖肿瘤中血管的生成。色素上皮衍生因子(pigment epithelium-derived factor,PEDF)是一种最有力的血管生成抑制剂,并被证实在骨肉瘤生长、侵袭和转移的过程中具有多种重要作用,故有望成为治疗骨肉瘤的新药物。 Osteosarcoma （OS） is a disease apt to afflict teenagers. The growth and metastasis of OS depend on tumor angio- genesis. Pigment epithelium-derived factor （PEDF） is one of the most potent inhibitors of angiogenesis, and has recently been demon- strated to have an important muhifunctional role in OS growth, invasion, and metastasis. PEDF therefore might be a promising thera- peutic agent for the treatment of patients with OS.
作者 赵则雪 吴苏稼
机构地区 南京大学医学院临床学院(南京军区南京总医院)骨科
出处 《医学研究生学报》 CAS 北大核心 2013年第3期323-325,共3页 Journal of Medical Postgraduates
关键词 色素上皮衍生因子 骨肉瘤 治疗 Pigment epithelium-derived factor Osteosarcoma Treatment
分类号 R738.1 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Simonovic M, Gettins PG, Volz K. Crystal structure of human PEDF, a potent anti-angiogenic and neurite growth-promoting factor[J]. Proc Natl Acad Sci, 2001,98(20) :11131-11135.
  • 2Steele FR, Chader GJ, Johnson LV, et al. Pigment epithelium- derived factor: neurotrophic activity and identification as a mem- ber of the serine protease inhibitor gene family [ J ]. Proc Natl Acad Sci (USA), 1993, 90(4) : 1526-1530.
  • 3Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor [ J ]. Trends Mol Med, 2003, 9 (6) : 244-250.
  • 4Becerra SP, SagastiA, Spinella P, et al. Pigment epithelium-de- rived factor behaves like a noninhibitory serpin. Neurotrophic ac- tivity does not require the serpin reactive loop [ J ]. J Biol Chem, 1995, 270(43): 25992-25999.
  • 5Becerra SP. Focus on Molecules: Pigment epithelium-derived fac- tor (PEDF)[J]. Exp, Eye Res, 2006, 82(5): 739-740.
  • 6Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium- derived factor : a potent inhibitor of angiogenesis [ J ]. Science, 1999, 285 (5425) : 245-248.
  • 7Hoshina D, Abe R Yamagishi S, et al. The role of PEDF in tumor growth and metastasis [ J]. Cur Mol Med, 2010,10 (3), 292-295.
  • 8黎承军,吴苏稼,施鑫.骨肉瘤新辅助化疗疗效评价方法研究进展[J].医学研究生学报,2007,20(11):1211-1213. 被引量：12
  • 9LinksEk ET, Dass CR, Choong PF. Pigment epithelium-derived factor:a muhimodal tumor inhibitor[J]. Mol Cancer Ther,2006, 5(7) :1641-1646.
  • 10Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor- specific nanoparticle delivery : effect of particle size [ J ]. Cancer Res, 2000, 60: 4440-4445.

二级参考文献68

  • 1郭卫,杨荣利,汤小东,唐顺,李大森,杨毅.成骨肉瘤新辅助化学药物治疗的疗效分析[J].中华医学杂志,2004,84(14):1186-1190. 被引量：25
  • 2邱俊骏,施鑫,赵建宁,吴苏稼.骨肉瘤化疗耐药相关基因的研究进展[J].医学研究生学报,2005,18(2):164-166. 被引量：8
  • 3郝晶,丁晓毅,陈克敏.骨肉瘤新辅助化疗效果的影像学评价[J].国外医学（骨科学分册）,2005,26(3):147-149. 被引量：1
  • 4陈志伟,吴苏稼.骨肉瘤组织中HER2、P-糖蛋白的表达与预后的关系[J].医学研究生学报,2005,18(5):462-464. 被引量：10
  • 5Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells [ J ]. Cell, 1998,94 (6) : 715 -725.
  • 6Hagendoorn J, Tong R, Fukumura D, et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis [ J ]. Cancer Res,2006,66 (7) : 3360-3364.
  • 7Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond[ J]. Cancer Metastasis Rev, 2007,26 (3- 4 ) :489-502.
  • 8Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tmnorigenesis [ J]. Cell, 1996,86 (3) :353-364.
  • 9Hillen F, Griffioen AW. Tumour vascularization: sprouting an-giogenesis and beyond [ J]. Cancer Metastasis Rev, 2007,26 (3- 4 ) :489-502.
  • 10Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor ( vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract [ J ]. Cancer Res, 1993,53(19) :4727-4735.

共引文献25

同被引文献43

  • 1Roth M. Linkowski M. TarimJ. et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.[J].Cancer.2014.120 (4) :548-554.
  • 2Luetke A. Meyers P A. Lewis I. et al. Osteosarcoma treatment?Where do we stand? A state of the art review.[J].Cancer Treatment Reviews.2013.40 (4) :523-532.
  • 3Miwa S. et al. Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing FrozenAutograft[J].PlosOne.2013.8 (8) :e71362.
  • 4Ma W. Fei K. Zhe W. et al. (99m) Tc-Iabeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice.[J].Amino Acids. 2013. 44 (5) :1337-1345.
  • 5Dondossola E. Corti A. Sidman R L. et al. Bone marrow-derived CD13+ cells sustain tumor progression[J].Oncoimmunology. 2014. 3 (2) :e27716-e27716.
  • 6Kansara M. et al. Immune response to RBI-regulated senescence limits radiation-induced osteosarcoma formation.[J].Journal of Clinical Investigation. 2013.123 (12) :5351-5360.
  • 7Basu-Roy U. Basilico C. et al. Perspectives on cancer stem cells in osteosarcoma[J].Cancer Letters. 2013. 338 (1) : 158-167.
  • 8Hoshi M. Ieguchi M. Yarnato K. et al. Diagnosis of osteosarcoma in a patient previously treated for Ewing sarcoma.[J].Skeletal Radiology.2014.43 (9) :1319-1324.
  • 9Lei H. Xinhan Z. Pei W. et al. Antitumor Activity of Antimicrobial Peptides Containing C isoDGRC in CD13 Negative Breast Cancer Cells[J].PlosOne.2013.8 (12) :e53491-e53491.
  • 10Eleonora D. et al. CD13-positive bone marrow-derived myeloid cells promote angiogenesis. tumor growth. and metastasis.[J]. Proceedings of the National Academy of Sciences of the United States of America. 2013.110 (51) :20717-20722.

引证文献3

二级引证文献13

医学研究生学报
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部